Table of Contents
MONTREAL and RESEARCH TRIANGLE PARK, N.C. — Renaissance Acquisition Holdings has entered into an agreement giving it the U.S. rights to manufacture, market and sell six dermatology and three antiviral products from GlaxoSmithKline.
The companies said Monday that that products, from GSK and and its Stiefel subsidiary, which will be marketed via Prestium Pharma, Renaissance’s branded drug division.
The nine products are Evoclin Foam 1% (clindamycin phosphate); Extina Foam 2% (ketoconazole); Luxiq Foam 0.12% (betamethasone valerate); Olux Foam 0.05% (clobetasol propionate); Olux-E Foam 0.05% (clobetasol propionate); Vusion Ointment (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%); and Zovirax (acyclovir) capsules, tablets and suspension.
"This transaction represents a significant milestone for Renaissance and is in line with our strategy of acquiring niche products that we can both manufacture within our internal network and market through our strong commercial group," stated Pierre Fréchette, president and chief executive officer of Montreal-based Renaissance, a RoundTable Healthcare Partners company.
Renaissance focuses on pharmaceutical contract development and manufacturing and commercialization of branded and generic drugs in the United States and Canada. Prestium focuses on acquiring, licensing and selling in-market branded prescription products, including mature brands with or without generic competition.
"We are excited to add these mature specialty brands to Prestium’s growing portfolio and look forward to continuing to supply such important products to our customers and to patients across the country," commented John Denman, general manager of Prestium.
Simon Jose, Stiefel President, said, “This agreement allows US patients to continue to have access to treatments they value and allows the Stiefel US Team to focus on growth and development of new treatments within our core dermatology portfolio.”
GSK’s Stiefel specializes in over-the-counter and prescription dermatology medications.
"This agreement allows U.S. patients to continue to have access to treatments they value and allows the Stiefel U.S. Team to focus on growth and development of new treatments within our core dermatology portfolio," stated Simon Jose, president of Stiefel.
